Drug Trial Radar · NCT05774873
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Aug 9, 2023
Primary completion
Mar 20, 2025
Study completion Mar 20, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is open-label, multicenter, Phase I/II study is designed to evaluate the Safety and tolerability and Efficacy of IBI334 Monotherapy in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
IBI334Drug
There are six dose of IBI334 ,QW IV in first cycle and Q2W IV behind the first cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with treatment-related adverse eventsTime frame: Up to 60 days post last dose
- Percentage of subjects woth Dose-Limitine toxicities(DLTs)Time frame: Up to 28 days following first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Shandong First Medical university
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.